Gen2 Neuroscience

Gen2 Neuroscience is a private UK biotechnology company developing disease-modifying therapies for dementia and related neurodegenerative disorders. The company focuses on toxic extracellular forms of tau and uses human stem cell-derived neuronal models to identify disease-associated tau species and develop targeted therapeutics. Its lead program, Gen2B, consists of anti-tau antibody therapeutics designed to block uptake of pathogenic tau while sparing normal tau. Gen2 was founded in 2016 and has been backed by the Dementia Discovery Fund. The company appears to remain in the preclinical stage, with a focused pipeline centered on tau-driven neurodegeneration.